(NASDAQ: CARA) Cara Therapeutics's forecast annual revenue growth rate of -25.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Cara Therapeutics's revenue in 2024 is $16,938,000.On average, 3 Wall Street analysts forecast CARA's revenue for 2024 to be $362,282,871, with the lowest CARA revenue forecast at $262,444,579, and the highest CARA revenue forecast at $543,478,983. On average, 3 Wall Street analysts forecast CARA's revenue for 2025 to be $351,183,653, with the lowest CARA revenue forecast at $170,588,976, and the highest CARA revenue forecast at $686,183,223.
In 2026, CARA is forecast to generate $397,494,186 in revenue, with the lowest revenue forecast at $82,013,931 and the highest revenue forecast at $905,433,798.